Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162412 | 0.89 | SMN1; SMN2 (0.82) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL29046318 | 0.88 | SMN1; SMN2 (0.58) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL14688250 | 0.85 | HPGD (0.63) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL6357661 | 0.81 | SGMS2 (0.52) | HPGDSMN1; SMN2RAB9ALMNAMAPT | |
| SCHEMBL2228385 | 0.81 | MEN1 (0.54) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL6647000 | 0.79 | SMN1; SMN2 (0.52) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL1849467 | 0.79 | MAPT (0.79) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL14818759 | 0.78 | MAPK1 (0.74) | HPGDSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL129968 | 0.78 | NPC1 (0.82) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL19579563 | 0.77 | SMN1; SMN2 (0.67) | HPGDSMN1; SMN2RAB9ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735384-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011090911-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APH1B | HPGD 2637/4885SMN1; SMN2 3351/4885RAB9A 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.